M&A / Deals Update: Lilly makes $7bn bid for in vivo CAR-T firm Kelonia PharmaphorumEli Lilly is paying $3.25bn upfront for in vivo CAR-T therapy developer Kelonia, with another $3.75bn on offer if its candidates perform as hoped.M&A / DealsOncologyRead full story pharminent April 20, 2026 (Last updated: April 20, 2026) Pharmaphorum Eli Lilly is paying $3.25bn upfront for in vivo CAR-T therapy developer Kelonia, with another $3.75bn on offer if its candidates perform as hoped. M&A / DealsOncologyRead full story Post navigation Previous: The Omnichannel Gap: Building the CRM of the Future for Patient ServicesNext: UK Knowledge Quarter welcomes Boehringer Ingelheim AI accelerator Related Stories M&A / Deals Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B pharminent May 13, 2026 M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal pharminent May 12, 2026 M&A / Deals Cellular Intelligence scoops up Novo’s Parkinson’s therapy pharminent May 12, 2026
